Sofwave is like re-stringing the springs so it can stretch and rebound again
we prioritize authentic, FDA-approved metabolic therapies The FDA has warned about dosing errors and adverse events involving compounded injectable semaglutide products
01 Metabolic Research Studied for its role in metabolic pathways and energy balance 02 Multi-Receptor Action Targets GLP-1, GIP, and glucagon receptors in ongoing research 03 High Purity Standards Manufactured under strict quality controls with verified batch testing
Retatrutide is not approved as a medicine, supplement, or therapeutic product in Thailand or any other major jurisdiction at the time of writing.
In contrast, oral semaglutide, even at higher doses, typically offers a bit less, with some studies reporting an average weight loss of 13.6% (source)
This is why every GLP-1 medication carries a warning against use in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
